Halozyme Therapeutics (NASDAQ:HALO) reported Q2 EPS of $0.53, $0.06 better than the analyst estimate of $0.47. Revenue for the quarter came in at $152.4 million versus the consensus estimate of $138.63 million.
GUIDANCE:
Halozyme Therapeutics sees FY2022 EPS of $2.10-$2.25, versus the consensus of $2.23. Halozyme Therapeutics sees FY2022 revenue of $655-685 million, versus the consensus of $610.9 million.